WeVote
Log In

Bill

Bill

H 1107

An Act prohibiting discrimination against 340b drug discount program participants

194th Legislature (2025-2026) Introduced by Dan Cahill and 20 co-sponsors

H 1107 - An Act prohibiting discrimination against 340B drug discount program participants OverviewBill Number: H 1107 Title: An Act prohibiting discrimination against 340B drug d

Accompanied a new draft, see H4490
0
WeVote Research Nonpartisan
Bill Summary · H 1107

H 1107 - An Act prohibiting discrimination against 340B drug discount program participants

Overview

Bill Number: H 1107
Title: An Act prohibiting discrimination against 340B drug discount program participants
Status: Accompanied a new draft, see H4490
Introduced: February 27, 2025

Purpose and Intent

The primary purpose of this bill is to prohibit discrimination against healthcare providers and pharmacies that participate in the federal 340B Drug Pricing Program. The 340B program requires drug manufacturers to provide outpatient drugs at discounted prices to eligible healthcare organizations that serve a disproportionate share of low-income and uninsured patients. This bill aims to protect these 340B program participants from being unfairly targeted or disadvantaged by drug manufacturers, insurers, or other entities.

Key Provisions

  • Prohibits drug manufacturers from taking actions to restrict, limit, or impede 340B program participants' access to 340B discounted drugs
  • Prohibits insurers and pharmacy benefit managers from discriminating against 340B program participants in terms of reimbursement rates, network participation, or other contractual requirements
  • Requires drug manufacturers to offer 340B discounted drugs to all eligible 340B program participants without restrictions
  • Empowers the Secretary of Health and Human Services to investigate and enforce compliance with the non-discrimination requirements

Affected Parties and Impacts

This bill would primarily impact the following parties:

  • Healthcare providers and pharmacies that participate in the 340B drug discount program, including hospitals, clinics, and community health centers that serve vulnerable populations
  • Drug manufacturers that are required to offer 340B discounted drugs
  • Health insurers and pharmacy benefit managers that contract with 340B program participants
  • Patients who receive care from 340B program participants, as the discounts help these providers offer more affordable medications and healthcare services

By prohibiting discrimination against 340B program participants, this bill aims to preserve the intended benefits of the 340B program and ensure continued access to discounted drugs for the vulnerable populations served by these healthcare providers.

Procedural and Timeline Considerations

This bill, H 1107, was introduced in the legislature on February 27, 2025. It has since been accompanied by a new draft, H4490, which may incorporate additional provisions or refinements. The current status is that the bill is progressing through the legislative process, but the timeline for potential passage and enactment remains uncertain. Further updates and amendments to the bill language may occur as it continues to be considered by lawmakers.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.